Results 51 to 60 of about 315,728 (345)
Immunogenicity of Extracellular Vesicles.
Advances in MaterialsExtracellular vesicles (EVs) are promising next-generation therapeutics and drug delivery systems due to demonstrated safety and efficacy in preclinical models and early-stage clinical trials. There is an urgent need to address the immunogenicity of EVs (
Yutian Xia +3 more
semanticscholar +1 more source
Assessing the Immunogenicity of Biopharmaceuticals [PDF]
BioDrugs, 2016 Biopharmaceuticals have the potential to raise an immunogenic response in treated individuals, which may impact the efficacy and safety profile of these drugs. As a result, it is essential to evaluate immunogenicity throughout the different phases of the clinical development of a biopharmaceutical, including post-marketing surveillance.
Carlos Pineda +4 more
openaire +2 more sources
mAbs, 2021 New challenges and other topics in non-clinical safety testing of biotherapeutics were presented and discussed at the nineth European BioSafe Annual General Membership meeting in November 2019.
Thomas Kissner +14 more
doaj +1 more source
Immunogenicity and humanization of single‐domain antibodies
The FEBS Journal, 2021 Single‐domain antibodies (sdAbs), the autonomous variable domains of camelid and shark heavy‐chain antibodies, have many desirable properties as components of biologic drugs.
M. Rossotti +3 more
semanticscholar +1 more source
Immunogenicity of Endolysin PlyC
Antibiotics, 2022 Endolysins are bacteriolytic enzymes derived from bacteriophages. They represent an alternative to antibiotics, since they are not susceptible to conventional antimicrobial resistance mechanisms. Since non-human proteins are efficient inducers of specific immune responses, including the IgG response or the development of an allergic response mediated ...
Marek Adam Harhala +4 more
openaire +3 more sources
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Molecular Therapy: Methods & Clinical Development, 2022 Immunogenicity has imposed a challenge to efficacy and safety evaluation of adeno-associated virus (AAV) vector-based gene therapies. Mild to severe adverse events observed in clinical development have been implicated with host immune responses against ...
Tong-yuan Yang +18 more
doaj
Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody
mAbs, 2022 Anti-drug antibodies (ADA) can limit the efficacy and safety of therapeutic antibodies. However, determining the exact nature of ADA interactions with the target drug via epitope mapping is challenging due to the polyclonal nature of the IgG response ...
Arthur J. Schick +5 more
doaj +1 more source
An integrated approach for characterizing immunogenic responses toward a bispecific antibody
mAbs, 2021 Bispecific antibodies (bsAbs) recognize and bind two different targets or two epitopes of the same antigen, making them an attractive diagnostic and treatment modality.
Sivan Cohen +14 more
doaj +1 more source
Nanomedicine‐Boosting Tumor Immunogenicity for Enhanced Immunotherapy
Advanced Functional Materials, 2021 Immunotherapy has revolutionized oncology remarkably and gained great improvements in cancer therapy. However, tumor immunotherapy still encounters serious challenges, especially certain tumors barely respond to immunotherapy.
Jing Huang +8 more
semanticscholar +1 more source
A dermatologist guide to immunogenicity
International Journal of Women's Dermatology, 2016 Dermatologists should be aware that autoantibody formation may occur after the initiation of biologic therapy. This phenomenon has been referred to as immunogenicity and biologic fatigue. Because of this, patients may experience loss of clinical efficacy to a particular drug.
Soham P. Chaudhari +3 more
openaire +4 more sources